Latest / The Well-Built Life / Stopping Cancer's Spread: Ketorolac’s Potential as a Metastasis Preventive
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Well, it's clear that Emory University
- 0:27Speaker 1: has just dropped a major bombshell in the oncology world
- 0:30Speaker 1: with their research on Ketorolac. For those tuning in who
- 0:34Speaker 1: might not be familiar, Ketorolac is a common painkiller often
- 0:38Speaker 1: used post-surgery to manage pain. Now, it's being suggested that
- 0:43Speaker 1: this drug could play a crucial role in preventing cancer
- 0:46Speaker 1: from spreading after a surgical removal of a tumor. What
- 0:50Speaker 1: do you make of this, Thomas?
- 0:52Speaker 2: It's quite compelling, Rachel. The initial reactions have been enthusiastic,
- 0:56Speaker 2: but also circumspect given the early stage of the research.
- 1:00Speaker 2: After all, we are not talking about a drug that's
- 1:03Speaker 2: been given a green light for widespread use just yet,
- 1:06Speaker 2: but the potential is truly staggering. The study shows that
- 1:10Speaker 2: Ketorolax significantly reduced metastatic tumors in mice, not just from
- 1:15Speaker 2: post-surgery pain but specifically around the time of surgery. How
- 1:20Speaker 2: does that resonate with you?
- 1:21Speaker 1: Exactly. because on the surface it looks straightforward. But when
- 1:25Speaker 1: you dig into the mechanics, the incentives tell a very
- 1:28Speaker 1: different story. The study found that Ketorolac enhanced the body's
- 1:32Speaker 1: immune response to target residual cancer cells, which is fascinating.
- 1:37Speaker 1: It's almost like the drug helps create a more vigilant
- 1:39Speaker 1: immune environment, right?
- 1:41Speaker 2: Absolutely. And that's the crucial nuance here. It's not just
- 1:45Speaker 2: about pain relief, it's about modulating the inflammation response to
- 1:48Speaker 2: aid immune surveillance. But let's not get too excited yet.
- 1:52Speaker 2: The researchers also tested a combo with aspirin and omega-3s,
- 1:57Speaker 2: which seemed to amplify the anti-metastatic effect. That really highlights
- 2:01Speaker 2: the complexity of these interactions, doesn't it? Right.
- 2:05Speaker 1: And it's key to note that while promising, the study
- 2:08Speaker 1: isn't definitive. The current data comes from mouse models, and
- 2:12Speaker 1: the transition to human trials involves numerous complexities. The potential
- 2:17Speaker 1: benefits must be weighed against the recognized risks of the drug.
- 2:21Speaker 1: which can include bleeding and kidney issues. We are diving
- 2:25Speaker 1: into a minefield here, aren't we?
- 2:28Speaker 2: Definitely. We have to ask, how do the findings translate?
- 2:32Speaker 2: Are we looking at a one-size-fits-all solution, or do we
- 2:37Speaker 2: need a tailored approach for different types of cancer and patients?
- 2:41Speaker 2: The timing and dosage of Ketorolac are going to be
- 2:44Speaker 2: super critical in these trials. The researchers would have to
- 2:48Speaker 2: fine-tune that aspect, no?
- 2:49Speaker 1: Precisely. And the debate doesn't end there. We have to
- 2:53Speaker 1: consider the long-term effects on patient recovery and quality of life.
- 2:56Speaker 1: It's not just about preventing metastasis. It's about ensuring that
- 3:00Speaker 1: any new treatment also doesn't compromise the patient's overall health.
- 3:04Speaker 1: This is where the rubber meets the road.
- 3:06Speaker 2: Thomas. That's a well-taken point. The future outlook is indeed
- 3:10Speaker 2: cautiously optimistic, yet full of questions. How can we optimally
- 3:14Speaker 2: combine Ketorolac with other anti-inflammatories? What are the long-term implications
- 3:20Speaker 2: on the treatment of cancer patients? These are the kinds
- 3:23Speaker 2: of details that will define whether this finding lives up
- 3:26Speaker 2: to its promise.
- 3:27Speaker 1: Agreed. The path ahead is fraught with challenges, but also
- 3:31Speaker 1: full of potential. It's an exciting time, and we will
- 3:34Speaker 1: certainly keep a close eye on the ongoing research and trials. Okay,
- 3:39Speaker 1: let's delve into the study mechanisms. First, How does Keterolac
- 3:44Speaker 1: enhance immune surveillance post-surgery?
- 3:47Speaker 2: Well, it's about creating a microenvironment that's more conducive to
- 3:50Speaker 2: the immune system's task. Keterolac works by reducing certain inflammatory signals,
- 3:56Speaker 2: which can actually help in boosting immune surveillance of residual
- 3:59Speaker 2: cancer cells.
- 4:00Speaker 1: Got it. And this isn't just a theoretical approach. They
- 4:04Speaker 1: are actually seeing quantitative data from mouse models that back
- 4:08Speaker 1: this up. Can you walk us through some of the
- 4:11Speaker 1: key metrics?
- 4:12Speaker 2: Absolutely. In the experiments, mice treated with Ketorolac had significantly
- 4:16Speaker 2: fewer metastatic tumors and prolonged survival rates. For instance, the
- 4:21Speaker 2: incidence of metastatic tumors was 50% lower in the treated
- 4:25Speaker 2: group compared to the controls.
- 4:27Speaker 1: That's a remarkable drop. And what about the combination with
- 4:31Speaker 1: aspirin and omega-3 fatty acids? How does that contribute to
- 4:36Speaker 1: the overall effectiveness?
- 4:37Speaker 2: The combination really adds a layer of synergy. The aspirin
- 4:41Speaker 2: and omega-3s seemed to further reduce inflammation and potentially enhance
- 4:47Speaker 2: the immune response. In the study, the treated group with
- 4:50Speaker 2: all three agents not only had fewer tumors, but they
- 4:54Speaker 2: also fared better in terms of overall survival.
- 4:57Speaker 1: Right, and that's the crucial nuance here. So, if we
- 5:00Speaker 1: step back, these findings could have major implications for cancer
- 5:04Speaker 1: prevention strategies. It's not just about reducing pain post-surgery. but
- 5:10Speaker 1: potentially changing the course of the disease entirely.
- 5:13Speaker 2: Exactly, which brings up an interesting contradiction. While the data
- 5:18Speaker 2: look promising, it's still just in mice. The success in
- 5:22Speaker 2: human patients isn't guaranteed. We need more controlled clinical trials
- 5:27Speaker 2: to see if these results hold up.
- 5:28Speaker 1: That's a fair point. The safety profile of Ketorolac is
- 5:32Speaker 1: also a concern, with potential side effects like bleeding and
- 5:35Speaker 1: kidney issues. How do we address these risks while still
- 5:39Speaker 1: exploring the benefits?
- 5:40Speaker 2: It's a balancing act. Researchers need to carefully manage the
- 5:44Speaker 2: dosing and timing of Ketorolac to minimize adverse effects while
- 5:48Speaker 2: maximizing its anti-inflammatory benefits. For now, it's about finding that
- 5:54Speaker 2: sweet spot where the drug's benefits outweigh the risks.
- 5:56Speaker 1: True. And what about the long-term effects of such treatments?
- 6:02Speaker 1: How do we ensure patient quality of life isn't compromised?
- 6:06Speaker 2: That's an ongoing question. The study will have to follow
- 6:10Speaker 2: patients for extended periods to see how they respond over time.
- 6:15Speaker 2: The goal is to develop a safe and effective noninvasive
- 6:18Speaker 2: strategy that doesn't just prevent cancer, but also allows patients
- 6:22Speaker 2: to maintain their quality of life.
- 6:25Speaker 1: Exactly. It's a complex puzzle, but one that holds great promise.
- 6:30Speaker 1: These findings are a clear step forward. but we have
- 6:33Speaker 1: a long way to go before we can apply this
- 6:35Speaker 1: knowledge in clinical settings.
- 6:37Speaker 2: Agreed. The path ahead is full of potential, but also challenges.
- 6:42Speaker 2: It's an exciting time and we will be keeping a
- 6:44Speaker 2: close eye on further research and trials to see where
- 6:47Speaker 2: this goes.
- 6:48Speaker 1: So, let's dive into the clinical implications. The mouse studies
- 6:52Speaker 1: are showing promising results, but we need to be cautious
- 6:55Speaker 1: about extrapolating these findings directly to humans. The mechanisms, while interesting,
- 7:01Speaker 1: could have quite different effects in our bodies.
- 7:04Speaker 2: Absolutely. The translation from mouse to human is a critical hurdle.
- 7:09Speaker 2: Do you remember the last time we discussed the differences
- 7:11Speaker 2: in microbiomes and immune systems between mice and humans? It's
- 7:16Speaker 2: not just about the drugs mechanism. There are entire host
- 7:19Speaker 2: factors at play.
- 7:20Speaker 1: Precisely. Take, for instance, the dosage. What worked in mice
- 7:24Speaker 1: might be toxic in humans, and the timing of when
- 7:27Speaker 1: we administer Ketorolac post-surgery is essential. If it's too early
- 7:32Speaker 1: or too late, its anti-inflammatory effects might either impair or
- 7:36Speaker 1: enhance the immune response in ways we can't predict.
- 7:39Speaker 2: Right, and that's the crucial nuance here. For example, in
- 7:43Speaker 2: clinical settings, we could face a Goldilocks problem. We need
- 7:47Speaker 2: to get the dosage and timing just right. Early trials
- 7:51Speaker 2: might be limited to low doses to minimize adverse effects,
- 7:54Speaker 2: like bleeding or kidney damage, which are well-known risks of
- 7:58Speaker 2: Ketorolac in humans.
- 7:59Speaker 1: Exactly, which brings up an interesting contradiction. The very attributes
- 8:04Speaker 1: that make Ketorolac useful as an analgesic, its anti-inflammatory properties,
- 8:10Speaker 1: could become a limitation in cancer prevention if not applied precisely.
- 8:15Speaker 1: It's a delicate balancing act.
- 8:16Speaker 2: That's wild when you look at the raw numbers. In
- 8:19Speaker 2: the studies, even small changes in dosage or timing led
- 8:23Speaker 2: to significantly different outcomes. This variability makes it challenging to
- 8:28Speaker 2: establish a standard protocol for human trials. And what about
- 8:31Speaker 2: different tumor types? Could the results seen in one kind
- 8:35Speaker 2: of cancer hold true for another?
- 8:36Speaker 1: Right. The consistency is a big question. We have seen
- 8:40Speaker 1: that some tumor types might respond better to Ketorolac than others.
- 8:44Speaker 1: This variability could affect the drug's broader applicability. For example,
- 8:50Speaker 1: Breast cancer might respond differently compared to lung cancer, both
- 8:54Speaker 1: in terms of efficacy and side effects.
- 8:56Speaker 2: Exactly, and the practical takeaway here is that we need
- 8:59Speaker 2: more research. We can't rush into large-scale human trials without
- 9:03Speaker 2: thoroughly addressing these variables. It's all about building a robust
- 9:07Speaker 2: research pipeline that includes smaller, more focused studies to pinpoint
- 9:11Speaker 2: the best protocols.
- 9:12Speaker 1: Agreed. The safety concerns, coupled with the complex interactions between
- 9:17Speaker 1: tumor types and patient populations, highlight the need for comprehensive,
- 9:22Speaker 1: multifaceted research. We are at an exciting, but also challenging juncture.
- 9:28Speaker 1: The potential benefits are great, but so are the risks.
- 9:31Speaker 2: Definitely. It's a clear call for further research and a
- 9:34Speaker 2: more nuanced approach in oncology. We need to unravel these
- 9:38Speaker 2: complexities to truly understand Ketorolax's full potential.
- 9:42Speaker 1: The key quotes from the study are quite compelling.
- 9:45Speaker 2: Absolutely.
- 9:46Speaker 1: And Dr. Jane Smith's quote about reduced in mice treated
- 9:51Speaker 1: with keterolac. That's a clear indication of its potential impact
- 9:55Speaker 1: on cancer care.
- 9:56Speaker 2: Absolutely. And Dr. Jane Smith's quote about inflammation modulation is crucial.
- 10:02Speaker 2: She is highlighting that the drug might help support immune surveillance,
- 10:06Speaker 2: something that could be transformative. But we need to dive
- 10:09Speaker 2: deeper into the ongoing research questions. Indeed.
- 10:13Speaker 1: One of the main questions now is how to optimize
- 10:15Speaker 1: the combination of keterolac with other anti-inflammatory agents. How do
- 10:21Speaker 1: we ensure we are not just masking symptoms, but actually
- 10:24Speaker 1: helping to prevent metastasis?
- 10:26Speaker 2: Great point. Another question is about the long-term effects. How
- 10:30Speaker 2: will patients recover and maintain their quality of life? While
- 10:34Speaker 2: reducing metastasis is crucial, we can't ignore the potential downsides,
- 10:39Speaker 2: like the safety concerns you mentioned, such as bleeding and
- 10:42Speaker 2: kidney issues.
- 10:44Speaker 1: Exactly. The future outlook is promising, but we need to
- 10:48Speaker 1: be very careful. The current research only shows some early promise.
- 10:53Speaker 1: We need larger, more diverse human trials to see if
- 10:57Speaker 1: these results hold up.
- 10:58Speaker 2: Right. And even then, the challenge will be to determine
- 11:01Speaker 2: the optimal timing and dosage. It's not a one-size-fits-all approach,
- 11:06Speaker 2: and we need to explore this carefully. Think about how
- 11:09Speaker 2: we can tailor this to different types of cancer and
- 11:12Speaker 2: patient populations.
- 11:13Speaker 1: Agreed. The next step is clearly defined, more research. We
- 11:18Speaker 1: need to establish these protocols through rigorous studies. And while
- 11:22Speaker 1: we are doing that, let's continue to explore the potential
- 11:26Speaker 1: of Ketorolac in combination therapies, but always with a focus
- 11:30Speaker 1: on safety and patient outcomes.
- 11:32Speaker 2: Well put, Rachel. And as we move forward, let's keep
- 11:35Speaker 2: the conversation open. We should continue to engage with the
- 11:39Speaker 2: broader community, share these findings, and encourage more voices to
- 11:43Speaker 2: join the research effort. It's going to be a collaborative journey.
- 11:47Speaker 2: but one that could truly revolutionize cancer care.
- 11:50Speaker 1: The strategic implications of this research are profound. We now
- 11:53Speaker 1: have a tool that, if successful, could revolutionize cancer care
- 11:58Speaker 1: by providing non-invasive methods to prevent metastasis. But the devil
- 12:02Speaker 1: is in the details, and Thomas, what do you make
- 12:05Speaker 1: of the broader picture?
- 12:06Speaker 2: Well, Rachel, it's certainly an exciting frontier. But we need
- 12:10Speaker 2: to be careful. While the preliminary data from the mouse
- 12:13Speaker 2: models is compelling, Translating those findings to humans is a
- 12:17Speaker 2: different beast entirely. The human immune system and tumor microenvironment
- 12:21Speaker 2: are incredibly complex. Not just one drug, but a delicate
- 12:25Speaker 2: balance of factors. Agreed.
- 12:27Speaker 1: And beyond the biological complexities, to rare's the economic angle.
- 12:32Speaker 1: If we find that Ketorolac can reduce metastasis at a
- 12:36Speaker 1: lower cost than current treatments, it could significantly impact healthcare systems.
- 12:41Speaker 1: But we also need to consider the pharmaceutical industry. which
- 12:44Speaker 1: could invest heavily in this research, potentially shaping both the
- 12:48Speaker 1: scope and pace of further studies.
- 12:51Speaker 2: Exactly. Speaking of industry, how do you see the involvement
- 12:55Speaker 2: of pharma companies shaping the landscape? Will they drive this
- 12:59Speaker 2: research forward or could it stall due to funding concerns?
- 13:02Speaker 1: That's a good question. If the promise of Ketorolac in
- 13:05Speaker 1: preventing metastasis becomes clear, major players might be more willing
- 13:09Speaker 1: to invest. But the potential for side effects like bleeding
- 13:13Speaker 1: and kidney issues could scare off some companies, especially if
- 13:16Speaker 1: the risk-benefit ratio isn't favorable.
- 13:19Speaker 2: It's a balancing act, for sure. On the flip side,
- 13:22Speaker 2: consider the role of governments and non-profits. They might see
- 13:25Speaker 2: this as an opportunity to support research that could significantly
- 13:28Speaker 2: improve public health outcomes, but their priorities and funding cycles
- 13:32Speaker 2: can be quite different from those of the for-profit sector. True.
- 13:36Speaker 1: And what about the role of patients and their advocates?
- 13:40Speaker 1: How would they be involved in these discussions? Their voices
- 13:43Speaker 1: are crucial. in ensuring that research is patient-centered.
- 13:47Speaker 2: Absolutely. Patient advocates could play a vital role in pushing
- 13:51Speaker 2: for transparent and inclusive trials. They can highlight the importance
- 13:56Speaker 2: of early-stage research, which often gets overlooked, and ensure that
- 14:00Speaker 2: the findings are practical for real-world applications.
- 14:03Speaker 1: That brings up another point. As we move forward, we
- 14:07Speaker 1: need to keep the conversation open, involving everyone from researchers
- 14:11Speaker 1: to policymakers and the general public. This collaboration is key
- 14:16Speaker 1: to making sure that the research is not only innovative,
- 14:19Speaker 1: but also ethical and accessible.
- 14:21Speaker 2: Well said, Rachel. And as we look ahead, the next
- 14:25Speaker 2: steps are clear, rigorous human trials. Let's see if the
- 14:29Speaker 2: same benefits are observed in people, and if they are,
- 14:33Speaker 2: how we can integrate Ketorolac into clinical practice effectively and safely.
- 14:38Speaker 2: The journey from bench to bedside is long. But with
- 14:41Speaker 2: the right partnerships and engagement, we could make a real difference.
- 14:44Speaker 1: That brings us to the end of today's episode. Thank
- 14:47Speaker 1: you so much for spending part of your day with me.
- 14:50Speaker 1: If you found this episode's tips helpful and want to
- 14:52Speaker 1: make sure you don't miss the next conversation, please take
- 14:55Speaker 1: a quick second to hit that subscribe or follow button
- 14:58Speaker 1: on whatever platform you are listening on. It's a completely
- 15:02Speaker 1: free way to support the show and helps more people
- 15:04Speaker 1: find us. This podcast is independently produced So if you
- 15:08Speaker 1: are ever in a position where you would like to
- 15:10Speaker 1: help keep it running, we do accept small donations. You
- 15:14Speaker 1: can find a link right in the episode description below
- 15:17Speaker 1: to buy us a coffee or contribute what you can.
- 15:20Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 15:25Speaker 1: and we will talk again soon.